Opinion|Videos|November 12, 2025
Applying Third-Line Therapy in mCRC: Community vs Academic Settings
Panelists discuss how community and academic settings differ in applying third-line therapies for metastatic colorectal cancer and how collaboration benefits patients.
Advertisement
Episodes in this series
Panelists describe clinical scenarios where patients may receive third-line therapy in community vs academic settings, noting differences in resources, expertise, and support.
Community practices may offer more accessibility and continuity of care, whereas academic centers may be better suited for complex cases or clinical trial enrollment.
They emphasize the importance of collaboration between settings to ensure equitable and consistent care for patients, regardless of treatment location.
Advertisement
Related to this article
Adults with moderately to severely active Crohn disease can now start risankizumab with an on-body injector at home.
For all the advances in breast cancer, there remains unmet need for patients whose cancer progresses after treatment with antibody-drug conjugates (ADCs). In the final week of Breast Cancer Awareness Month, AJMC® looks at an investigational vaccine approach that could come after ADCs, offering patients a low-toxicity regimen.
Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.
Advertisement
Advertisement
Trending on AJMC
1
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
2
Preparing for Hepatitis B Functional Cure: Jordan Feld, MD, MPH
3
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
4
Nephrologists Weigh Wins, Losses From 5 Years of Value-Based Kidney Care
5